Nextech Invest

Nextech Invest is a highly specialized venture capital firm headquartered in Zurich, Switzerland, with a dedicated focus on the oncology sector. Established in 1998, the firm has cultivated a strong reputation for identifying and supporting innovative companies that are developing groundbreaking cancer therapeutics. Their investment strategy is centered on private oncology companies across various stages, ranging from early-stage research and development to advanced clinical-stage trials, primarily within the United States and Europe.

The firm manages substantial capital, underscoring its commitment to the capital-intensive biotech industry. For instance, Nextech Invest successfully closed its fourth fund, Nextech Invest IV, at $150 million in 2017, followed by Nextech Invest V, which secured $200 million in 2021. These significant fund sizes enable Nextech to make meaningful investments in promising ventures. They typically aim to invest in 10 to 12 companies per fund, reserving considerable capital for follow-on rounds to support their portfolio companies through critical development milestones.

Nextech Invest's initial check sizes typically range from $5 million to $15 million, reflecting their capacity to support companies with substantial capital needs for drug discovery and clinical development. Their portfolio includes companies that have achieved notable successes, such as Blueprint Medicines, which went public, and others like Alector and PMV Pharmaceuticals, which have advanced their therapeutic pipelines. The firm's deep expertise in oncology, combined with its strategic capital deployment, positions it as a key player in the life sciences venture capital landscape, particularly for companies aiming to revolutionize cancer treatment.